Mark Levick

1 result

Novartis Institutes for BioMedical Research building in Cambridge, Massachusetts. Photograph: Scott Eisen/Bloomberg

Novartis on Friday touted safety and efficacy of its biosimilar copies of Johnson & Johnson’s Remicade and Amgen’s Enbrel, citing a study it hopes(...)